MA53002A - Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 - Google Patents
Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2Info
- Publication number
- MA53002A MA53002A MA053002A MA53002A MA53002A MA 53002 A MA53002 A MA 53002A MA 053002 A MA053002 A MA 053002A MA 53002 A MA53002 A MA 53002A MA 53002 A MA53002 A MA 53002A
- Authority
- MA
- Morocco
- Prior art keywords
- cannabinoid
- pyrazine
- pyridine
- new compounds
- receptor inhibitors
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title 1
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180137 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53002A true MA53002A (fr) | 2021-05-05 |
Family
ID=62814868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053002A MA53002A (fr) | 2018-06-27 | 2019-06-25 | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12071420B2 (fr) |
| EP (1) | EP3814329B1 (fr) |
| JP (1) | JP7445610B2 (fr) |
| KR (1) | KR102790077B1 (fr) |
| CN (2) | CN112262132A (fr) |
| AU (2) | AU2019294256B2 (fr) |
| BR (1) | BR112020025013A2 (fr) |
| CA (1) | CA3096777A1 (fr) |
| CL (1) | CL2020003331A1 (fr) |
| CO (1) | CO2020011855A2 (fr) |
| CR (1) | CR20200643A (fr) |
| IL (1) | IL279725B2 (fr) |
| MA (1) | MA53002A (fr) |
| MX (1) | MX2020012760A (fr) |
| PE (1) | PE20210368A1 (fr) |
| PH (1) | PH12020552152A1 (fr) |
| SG (1) | SG11202009103WA (fr) |
| WO (1) | WO2020002320A1 (fr) |
| ZA (1) | ZA202005426B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006030671B4 (de) | 2006-07-04 | 2008-10-02 | Moeller Gmbh | Schutzschalter-Kurzschließer-Kombination |
| CN110753690B (zh) | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
| EP3813888B1 (fr) | 2018-06-27 | 2025-11-26 | F. Hoffmann-La Roche AG | Ligand du récepteur cannabinoïde 2 radiomarqué |
| JP7454512B2 (ja) | 2018-06-27 | 2024-03-22 | エフ． ホフマン－ラ ロシュ アーゲー | 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体 |
| MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| WO2020002280A1 (fr) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Nouveaux composés de pyridine et de pyrazine substitués par azétidine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| JP2024541968A (ja) | 2021-10-28 | 2024-11-13 | ジェネンテック， インコーポレイテッド | 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2176251T3 (es) | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| JP2007523206A (ja) * | 2004-02-24 | 2007-08-16 | グラクソ グループ リミテッド | Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用 |
| GB0418047D0 (en) | 2004-08-12 | 2004-09-15 | Syngenta Participations Ag | Fungicidal compositions |
| US7776889B2 (en) | 2005-03-31 | 2010-08-17 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| JP5064506B2 (ja) * | 2006-10-04 | 2012-10-31 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体 |
| EP2311443A1 (fr) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Composition pharmaceutique contenant des antagonistes de récepteur de cannabinoïde-2 |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| WO2013028590A1 (fr) | 2011-08-25 | 2013-02-28 | Merck Sharp & Dohme Corp. | Inhibiteurs pyrimidines de pde10 |
| US9403808B2 (en) | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| CN104903466B (zh) | 2012-11-05 | 2016-11-23 | 鲁比康基因组学公司 | 条形编码核酸 |
| HRP20171459T1 (hr) | 2012-12-07 | 2017-11-03 | F. Hoffmann - La Roche Ag | Piridin-2-amidi korisni kao agonisti cb2 |
| JP6426619B2 (ja) | 2012-12-07 | 2018-11-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｂ２アゴニストとして有用なピリジン−２−アミド |
| PL2928882T3 (pl) | 2012-12-07 | 2017-07-31 | F.Hoffmann-La Roche Ag | Pochodne pirazyny jako agoniści receptora cb2 |
| EP3357918A1 (fr) | 2012-12-07 | 2018-08-08 | F. Hoffmann-La Roche AG | Nouveaux dérivés de pyridine |
| SI2978755T1 (en) | 2013-03-26 | 2018-03-30 | F. Hoffmann-La Roche Ag | New pyridine derivatives |
| EP3126359A1 (fr) | 2014-04-04 | 2017-02-08 | F. Hoffmann-La Roche AG | Pyridine-2-amides utiles comme agonistes de cb2 |
| AU2015239537B2 (en) * | 2014-04-04 | 2019-04-04 | Eidgenoessische Technische Hochschule Zuerich | 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists |
| WO2016066534A1 (fr) | 2014-10-27 | 2016-05-06 | F. Hoffmann-La Roche Ag | Ligands radiomarqués du récepteur cannabinoïde 2 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| BR112018011562B1 (pt) | 2015-12-09 | 2023-05-02 | F. Hoffmann-La Roche Ag | Novos derivados de fenil |
| US11479807B2 (en) | 2017-03-23 | 2022-10-25 | University Of Washington | Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| CN110753690B (zh) | 2017-06-20 | 2023-12-05 | 豪夫迈·罗氏有限公司 | 吡啶衍生物 |
| EP3793547A4 (fr) | 2018-05-15 | 2021-11-17 | H. Lundbeck A/S | Inhibiteurs de magl |
| JP7454512B2 (ja) | 2018-06-27 | 2024-03-22 | エフ． ホフマン－ラ ロシュ アーゲー | 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体 |
| MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| EP3813888B1 (fr) | 2018-06-27 | 2025-11-26 | F. Hoffmann-La Roche AG | Ligand du récepteur cannabinoïde 2 radiomarqué |
| WO2020002280A1 (fr) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Nouveaux composés de pyridine et de pyrazine substitués par azétidine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| TWI687701B (zh) | 2018-12-05 | 2020-03-11 | 宏碁股份有限公司 | 判斷電量狀態的方法及其電子裝置 |
-
2019
- 2019-06-25 MA MA053002A patent/MA53002A/fr unknown
- 2019-06-25 MX MX2020012760A patent/MX2020012760A/es unknown
- 2019-06-25 CN CN201980025482.7A patent/CN112262132A/zh active Pending
- 2019-06-25 WO PCT/EP2019/066811 patent/WO2020002320A1/fr not_active Ceased
- 2019-06-25 CN CN202411199620.2A patent/CN119161323A/zh active Pending
- 2019-06-25 KR KR1020217001909A patent/KR102790077B1/ko active Active
- 2019-06-25 BR BR112020025013-9A patent/BR112020025013A2/pt unknown
- 2019-06-25 SG SG11202009103WA patent/SG11202009103WA/en unknown
- 2019-06-25 PE PE2020001433A patent/PE20210368A1/es unknown
- 2019-06-25 CR CR20200643A patent/CR20200643A/es unknown
- 2019-06-25 CA CA3096777A patent/CA3096777A1/fr active Pending
- 2019-06-25 JP JP2020568525A patent/JP7445610B2/ja active Active
- 2019-06-25 EP EP19733484.0A patent/EP3814329B1/fr active Active
- 2019-06-25 IL IL279725A patent/IL279725B2/en unknown
- 2019-06-25 AU AU2019294256A patent/AU2019294256B2/en active Active
-
2020
- 2020-08-31 ZA ZA2020/05426A patent/ZA202005426B/en unknown
- 2020-09-24 CO CONC2020/0011855A patent/CO2020011855A2/es unknown
- 2020-12-14 PH PH12020552152A patent/PH12020552152A1/en unknown
- 2020-12-17 US US17/125,650 patent/US12071420B2/en active Active
- 2020-12-21 CL CL2020003331A patent/CL2020003331A1/es unknown
-
2024
- 2024-07-26 US US18/785,279 patent/US20240383872A1/en active Pending
- 2024-09-12 AU AU2024219640A patent/AU2024219640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL279725B1 (en) | 2023-12-01 |
| EP3814329B1 (fr) | 2024-01-17 |
| BR112020025013A2 (pt) | 2021-03-23 |
| US20240383872A1 (en) | 2024-11-21 |
| ZA202005426B (en) | 2025-06-25 |
| SG11202009103WA (en) | 2020-10-29 |
| CR20200643A (es) | 2021-05-11 |
| US12071420B2 (en) | 2024-08-27 |
| PE20210368A1 (es) | 2021-02-26 |
| WO2020002320A1 (fr) | 2020-01-02 |
| AU2019294256B2 (en) | 2024-06-20 |
| IL279725B2 (en) | 2024-04-01 |
| MX2020012760A (es) | 2021-03-25 |
| CN112262132A (zh) | 2021-01-22 |
| EP3814329A1 (fr) | 2021-05-05 |
| PH12020552152A1 (en) | 2021-07-05 |
| EP3814329C0 (fr) | 2024-01-17 |
| CL2020003331A1 (es) | 2021-05-07 |
| CN119161323A (zh) | 2024-12-20 |
| JP7445610B2 (ja) | 2024-03-07 |
| US20210115011A1 (en) | 2021-04-22 |
| IL279725A (en) | 2021-03-01 |
| JP2021529157A (ja) | 2021-10-28 |
| KR102790077B1 (ko) | 2025-04-03 |
| CA3096777A1 (fr) | 2020-02-02 |
| KR20210028202A (ko) | 2021-03-11 |
| CO2020011855A2 (es) | 2020-10-20 |
| AU2019294256A1 (en) | 2020-09-24 |
| AU2024219640A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA53219A (fr) | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase | |
| EP3464272A4 (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA52189A (fr) | Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA52754A (fr) | Composés hétérocycliques tricycliques en tant qu'activateurs de sting | |
| EP3755311A4 (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
| EP3856719A4 (fr) | Composés en tant qu'antagonistes du récepteur 3 de l'histamine neuronale et leurs utilisations | |
| EP3558974A4 (fr) | Composés et méthodes pour la dégradation ciblée d'activateur du polypeptide homologue 2 de zeste | |
| EP3807253A4 (fr) | Composés cyano quinoléine amide utilisés en tant qu'inhibiteurs de her2 et procédés d'utilisation | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| EP3570832A4 (fr) | Nouveaux composés utiles en tant qu'inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| IL279725A (en) | Pyridine and pyrazine compounds as cannabinoid receptor 2 inhibitors | |
| EP3448522A4 (fr) | Nouveaux composés d'imidazopyridine substitués en tant qu'inhibiteurs d'indoléamine 2,3-dioxygénase et/ou de tryptophane-2,3-dioxygénase | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 | |
| MA56208A (fr) | Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase | |
| EP3728232A4 (fr) | Nouveaux composés de quinolone utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine du domaine bcl6 btb et/ou en tant qu'agents de dégradation de bcl6 | |
| IL280047A (en) | Formulation of cannabinoid compounds |